Clinical Trial Update: Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies [Phase 1]

View source ↗

Summary

The update reports completion of a Phase I dose-escalation trial of BAY94-9343 given intravenously every three weeks in Japanese patients with advanced cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BAY94-9343

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED